---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056292"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:16:03.882365+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma Q1 net loss $93.8M; Phase 3 readouts on track for 2024

## Summary
- Enrolled over 9,500 patients in Phase 3 PREVAIL CVOT; topline data from BROOKLYN in Q3 2024 and BROADWAY in Q4 2024.
- Cash position $481.1M at March 31, vs $340.5M Dec 31, bolstered by $190M public offering.
- Net loss $93.8M ($1.06/diluted share) vs $42.0M ($0.51) year ago; revenue fell to $1.4M from $8.6M.
- Dosed first patients in TANDEM (fixed-dose obicetrapib/ezetimibe); topline expected Q1 2025.
- Appointed William H. Lewis as Board Chair and Juliette Audet as Chief Business Officer.

## SEC filing metadata
- accession: 0000950170-24-056292
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000095017024056292/0000950170-24-056292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000095017024056292/nams-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056292
- JSON: https://secwatch.observer/filing/0000950170-24-056292.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056292.txt

## Key facts
- Earnings Releases
  NewAmsterdam Pharma Co N.V. reported financial results for quarter ended March 31, 2024.
  - Period: quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, NewAmsterdam Pharma Company N.V. (the “Company”) issued a press release announcing corporate updates and its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1936258/000095017024056292/0000950170-24-056292-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.